Merck slips following its Q2 results as Gardasil sales slump. However, Keytruda, new launches and a rich pipeline bolster its ...

Merck (MRK) recently announced positive topline results from its Phase 3 KEYNOTE-905 trial, showcasing efficacy for KEYTRUDA in patients with muscle-invasive bladder cancer, which adds substantial ...

Sanofi said on Tuesday it had stopped supplying Praluent, a popular cholesterol drug jointly developed by the French ...

The system for compensating people injured by vaccines needs significant reform. But the health secretary could alter it in ...

Health Secretary Robert F. Kennedy Jr. says he wants to rework the U.S. program for compensating Americans injured by ...

Health Secretary Robert F. Kennedy Jr. is vowing to "fix" the federal program for compensating Americans injured by vaccines, ...

Merck's Phase 3 trial shows Keytruda plus Padcev improves survival in muscle-invasive bladder cancer patients ineligible for ...

Merck & Co., Inc. has kicked off two Phase 3 trials for its experimental PrEP therapy, MK-8527. **The trials, EXPrESSIVE-10 ...

Merck rose 1.17% on a trading day, showcasing a volume of $870M and a 121st rank in activity. Analysts are sending mixed ...